Preservation of the immunomodulatory effect of interval hypoxytherapy after coronavirus infection in the long-term period

The new coronavirus infection COVID-19, due to the complex pathogenesis of the disease, systemic impact on organs, the development of complications and persistent disorders after the infection, remains an important medical problem. Every year the number of patients with postcovid syndrome in need of timely and full rehabilitation is increasing. Recently, isolated work began to appear on the use of interval hypoxytherapy for the treatment of patients with coronavirus infection. The purpose of our study was to identify the long-term results of the effect of interval hypoxytherapy on the immunological and coagulation status of patients after suffering coronavirus infection COVID-19. 170 patients aged 45 to 59 years were examined after a moderate coronavirus infection before, after and three months after interval hypoxytherapy. The number of lymphocytes, immunoglobulins A, M, G, E and cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNFα) in blood, blood D-dimer, prothrombin time, fibrinogen in blood, antithrombin III, C-reactive was determined protein and ferritin in the blood. The conducted studies revealed changes in immunological reactivity after the coronavirus infection COVID-19, requiring correction. Interval hypoxytherapy had an immunomodulatory effect and led to the normalization of the main immunological parameters, which remained three months after hypoxytherapy: there was a significant (p < 0.05) increase in the number of CD3⁺T lymphocytes, CD4⁺T lymphocytes, CD8⁺T lymphocytes. The improvement in immune status was also evidenced by the normalization of the immunoregulatory index, an increase in the level of immunoglobulins A and G. The decrease in immunoglobulins E in the blood was an indicator of a decrease in the severity of sensitization of the body. The course of hypoxytherapy led to a decrease in the content of pro-inflammatory cytokines: IL-1β, IL-2, IL-6, IL-8, TNFα and an increase in anti-inflammatory cytokines: IL-4 and IL-10 in the blood, which indicated an attenuation of the inflammatory process in the lung tissue and in the body as a whole. Blood ferritin decreased 3 months after hypoxytherapy. As studies have shown, the effect of hypoxytherapy persists for three months after the course of treatment. Thus, interval hypoxytherapy can be recommended for the rehabilitation of patients after a moderate coronavirus infection. A repeated course of hypoxytherapy may be performed three months after the first course of hypoxytherapy.

1. Abdurakhimov A.Kh., Hegai L.N., Yusupova Sh.K. COVID-19 and its complications. Re-Health Journal, 2021, no. 4, pp. 61-65. (In Russ.)

2. Arachchillage D.R.J., Laffan M. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, Vol. 18, no. 5. pp. 1233-1234.

3. Balykin M.V., Sagidova S.A., Zharkov A.S., Aiziatulova E.D., Pavlov D.A., Antipov I.V. Effect of intermittent hypobaric hypoxia on HIF-1A expression and morphofunctional changes in the myocardium. Ulyanovsk MedicoBiological Journal, 2017, no. 2, pp. 125-134. (In Russ.)

4. Becker R.C. COVID-19 update: COVID-19-associated coagulopathy. J. Thromb. Thrombolysis, 2020, no. 1, pp. 54-67.

5. Borukaeva I.Kh., Abazova Z.Kh., Ivanov A.B., Shkhagumov K.Y. The role of interval hypoxytherapy and enteral oxygen therapy in the rehabilitation of patients presenting with chronic obstructive pulmonary disease. Problems of Balneology, Physiotherapy and Exercise Therapy, 2019, Vol. 96, no. 2, pp. 27-32. (In Russ.)

6. Borukaeva I.Kh., Abazova Z.Kh., Temirzhanova F.Kh., Yusupova M.M. COVID-19: observations on standard treatment algorithms. Medical Immunology (Russia), 2021, Vol. 23, no. 4, pp. 909-914. (In Russ.) doi: 10.15789/1563-0625-COO-2265.

7. Cummins E.P., Keogh C.E., Crean D., Taylor C.T. The role of HIF in immunity and inflammation. Mol. Aspects Med., 2016, Vol. 4, no. 48, pp. 24-34.

8. Harris A.J., Thompson A.R., Whyte M.K., Walmsley S.R. HIF-mediated innate immune responses: cell signaling and therapeutic implications. Hypoxia (Auckl), 2014, no. 2, pp. 47-58.

9. Huertas A., Montani D., Savale L., Pichon J.,Tu L., Parent F., Guignabert Ch., Humbert M. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19). Eur. Respir. J., 2020, Vol. 56, no. 1, 2001634. doi: 10.1183/13993003.01634-2020.

10. Ignatenko G.A. Application of interval normobaric hypoxytherapy in patients with cardiopulmonary pathology. Bulletin of Hygiene and Epidemiology, 2018, Vol. 22, no. 4, pp. 22-25. (In Russ.)

11. O’Sullivan J.M., Gonagle D.M., Ward S.E. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol., 2020, Vol. 7, no. 8, pp. 553-555.

12. Taylor C.T., Doherty G., Fallon P.G., Cummins E.P. Hypoxia-dependent regulation of inflammatory pathways in immune cells. J. Clin. Invest., 2016, Vol. 126, no. 1, pp. 3716-3724.

13. Titova O.N., Kuzubova N.A., Lebedeva E.S. The role of hypoxia signaling pathway in cell adaptation to hypoxia. RMJ. Medical Review, 2020, Vol. 4, no. 4, pp. 207-213. (In Russ.)

14. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet, 2020, Vol. 395, no. 10234, pp. 1417-1418.

15. Vasilenko I.A., Grigoryev G.I. Effective rehabilitation after COVID-19: interval hypo-hyperoxic training. Chief Physician, 2021, Vol. 2, no. 77, p. 27. (In Russ.)